- Home
- JRVR vs PRQR Comparison
JRVR vs PRQR Comparison
Compare JRVR & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | PRQR |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 244.1M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | JRVR | PRQR |
|---|---|---|
| Price | $4.62 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $7.33 | $7.25 |
| AVG Volume (30 Days) | 349.7K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.76 | $1.33 |
| 52 Week High | $7.20 | $3.10 |
Technical Indicators
Market Signals| Indicator | JRVR | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 55.17 |
| Support Level | $4.38 | $1.37 |
| Resistance Level | $4.69 | $1.99 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 51.61 | 61.86 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.